CriticalAntianginal – late sodium current inhibitor×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
The liver and gut break down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6 (ranolazine label, US Food and Drug Administration, FDA). Voriconazole is a strong CYP3A4 inhibitor and can raise the levels of drugs that this enzyme metabolises. The size of the increase depends on the drug (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The documents report no study of this pair. Another strong CYP3A4 inhibitor, ketoconazole 200 mg twice daily, increased the area under the concentration-time curve (AUC) of ranolazine 3.0–3.9-fold (ranolazine SmPC, EMA). Higher ranolazine levels raise the risk of its dose-dependent adverse effects, such as nausea and dizziness, and prolong the corrected QT interval (QTc) further (ranolazine SmPC, EMA). Voriconazole itself has been associated with QTc prolongation (voriconazole SmPC, EMA). According to the ranolazine SmPC, combining ranolazine with other QTc-prolonging drugs carries a theoretical risk of ventricular arrhythmias (ranolazine SmPC, EMA).
Symptoms
Dizziness, nausea and vomiting become more frequent as the ranolazine dose rises. In an intravenous overdose study in healthy volunteers, double vision, lethargy and fainting also occurred (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Oral ranolazine overdose has caused low blood pressure, QT prolongation, slow heart rate, muscle jerks, severe tremor, unsteady gait and incoordination, dizziness, nausea, vomiting, speech difficulty and hallucinations. Extreme overdose has been fatal (ranolazine label, US Food and Drug Administration, FDA). Torsade de pointes has rarely been reported in people receiving voriconazole, usually with other risk factors such as previous cardiotoxic chemotherapy, cardiomyopathy, low potassium and concomitant medicines (voriconazole SmPC, EMA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram. Ventricular arrhythmias cause palpitations, dizziness and fainting.
Management
The combination is contraindicated. The EU ranolazine summary of product characteristics (SmPC) contraindicates strong inhibitors of the enzyme CYP3A4 and names voriconazole among them (ranolazine SmPC, European Medicines Agency, EMA). The US ranolazine label contraindicates strong CYP3A inhibitors, and the US voriconazole label describes voriconazole as a strong CYP3A4 inhibitor (ranolazine and voriconazole labels, US Food and Drug Administration, FDA). The voriconazole documents do not name ranolazine. They contraindicate drugs that depend heavily on CYP3A4 for their metabolism and whose high levels can cause serious or life-threatening reactions. They also state that their lists are a guide and not complete (voriconazole SmPC, EMA, and FDA label). No document says how long to wait after stopping voriconazole before starting ranolazine. The EU voriconazole SmPC contraindicates QTc-prolonging drugs whose levels voriconazole may also raise through CYP3A4, and by its own SmPC ranolazine fits this description. Use voriconazole with caution with other QTc-prolonging drugs (voriconazole and ranolazine SmPCs, EMA). Monitor and correct low potassium, magnesium and calcium before and during voriconazole treatment (voriconazole SmPC, EMA, and FDA label). If ranolazine has nevertheless been taken with voriconazole and signs of ranolazine overdose appear, monitor the patient closely and give symptomatic and supportive treatment. Continuous electrocardiogram (ECG) monitoring may be needed. Haemodialysis is unlikely to clear ranolazine fully, because about 62% of it binds to plasma proteins (ranolazine SmPC, EMA, and FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Ranolazina (EU/1/08/462), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 08462001 (EU/1/08/462), secciones 4.3, 4.5 y 4.9, consultado 10/2026